Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Sana Biotechnology Inc (SANA) Price & Performance

Allbirds IncTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Sana Biotechnology Inc — how do they compare? Allbirds Inc trades at $2.59 (market cap $30.00M), while Sana Biotechnology Inc trades at $3.85 (market cap $1.13B). The key difference: Sana Biotechnology Inc is far larger — about 37.7× Allbirds Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.

BIRDSANA
Market Cap
$30.00M$1.13B
Sector
Consumer CyclicalHealth
52-Week High
$16.99$5.92
52-Week Low
$2.21$2.68
Enterprise Value
$48.86M$1.05B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD stock trades at $2.61, up 1.16% with a bullish technical signal despite mixed moving averages. The company has pivoted from footwear to AI infrastructure, rebranding as Smartbird in June 2026. Revenue declined from $298M in 2022 to $152M in 2025, with persistent negative net margins (-53.36%) and cash burn. Analyst consensus shows 21% buy ratings amid high hold percentage.

The outlook hinges on successful AI strategy execution, but significant risks include sustained losses, declining revenue, and cash flow challenges. Current valuation at P/S 0.15 appears low, yet profitability remains distant. Investors face binary outcome: AI pivot success could drive upside, while failure risks further declines.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.

The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.

Returns comparison

Trailing returns across standard periods

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA